代谢特征对非酒精性脂肪性肝病患者肝硬化及肝癌风险的影响
该回顾性队列纳入2004至2008年退伍军人事务部130家机构诊断的非酒精性脂肪性肝病患者271,906例,随访至2015年。平均9年随访期间22,794例发生肝硬化、253例发生肝癌;每增加一项代谢特征,肝硬化/肝癌风险逐步升高,糖尿病与肝癌关联最强。
要点
- 每增加一项代谢特征(糖尿病、高血压、血脂异常、肥胖),肝硬化及肝癌风险逐步升高。
- 合并糖尿病、肥胖、血脂异常和高血压者进展风险为无代谢特征者的2.6倍。
- 糖尿病与肝癌关联最强,合并糖尿病及高血压、肥胖者可能是二级预防重点人群。
核心结论
- 在非酒精性脂肪性肝病患者中,每增加一项代谢特征均会升高肝硬化及肝癌风险。
- 糖尿病赋予最高的肝癌进展风险。
- 合并糖尿病、高血压和肥胖的患者可能是二级预防的重要目标人群。
研究设计与样本
- 共纳入271,906例患者,采用竞争风险校正的病因特异性Cox模型评估代谢特征对肝硬化、肝癌及复合终点的时间效应。
主要发现
- 平均9年随访期间,22,794例发生肝硬化,253例发生肝癌。
- 基线平均体重指数31.6(SD 5.6),28.7%有糖尿病,70.3%有高血压,62.3%有血脂异常,各代谢特征间存在明显重叠。
- 仅有一项或无代谢特征者进展风险最低,每增加一项代谢特征风险逐步升高。
- 与无代谢特征者相比,同时合并高血压和血脂异常者进展至肝硬化/肝癌的风险高1.8倍(HR=1.8,95%CI=1.59-2.06)。
- 合并糖尿病、肥胖、血脂异常和高血压者风险高2.6倍(HR=2.6,95%CI=2.3-2.9),且这些关联对肝癌更强。
关键数值与推荐
- 同时合并高血压和血脂异常者进展至肝硬化/肝癌的HR=1.8(95%CI=1.59-2.06)。
- 合并糖尿病、肥胖、血脂异常和高血压者进展至肝硬化/肝癌的HR=2.6(95%CI=2.3-2.9)。
临床怎么用
- 对非酒精性脂肪性肝病患者应评估代谢特征数量,代谢特征越多进展风险越高。
- 合并糖尿病者应重点关注肝癌监测,尤其同时存在高血压和肥胖时。
- 合并糖尿病、高血压和肥胖的非酒精性脂肪性肝病患者可作为二级预防的重点目标人群。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Nonalcoholic fatty liver disease (NAFLD) is now the most common liver condition. Predicting its progression could help clinicians manage and potentially prevent complications. We evaluated the independent and joint effects of metabolic traits on the risk of cirrhosis and hepatocellular carcinoma (HCC) among patients with NAFLD. APPROACH AND RESULTS: We assembled a retrospective cohort of patients with NAFLD diagnosed at 130 facilities in the Veterans Administration between January 1, 2004, and December 31, 2008, with follow-up through December 31, 2015. We performed competing risk-adjusted cause-specific Cox models to evaluate the effects of metabolic traits (diabetes, hypertension, dyslipidemia, obesity) as additive or combined indicators on time to develop cirrhosis or HCC or a composite endpoint of both. Of the 271,906 patients, 22,794 developed cirrhosis, and 253 developed HCC during a mean of 9 years follow-up. At baseline, the mean body mass index was 31.6 (SD, 5.6), 28.7% had diabetes, 70.3% had hypertension, and 62.3% had dyslipidemia with substantial overlap among these traits. The risk of progression was the lowest in patients with only one or no metabolic trait. There was a stepwise increase in risk with each additional metabolic trait. Compared with patients with no metabolic trait, patients with both hypertension and dyslipidemia had 1.8-fold higher risk of progression to cirrhosis/HCC (hazard ratio [HR] = 1.8, 95% confidence interval [CI] = 1.59-2.06); the risk was 2.6-fold higher in patients with diabetes, obesity, dyslipidemia, and hypertension (HR = 2.6, 95% CI = 2.3-2.9). These associations were stronger for HCC. Diabetes had the strongest association with HCC in this cohort. CONCLUSIONS: Each additional metabolic trait increased the risk of cirrhosis and HCC in patients with NAFLD. Diabetes conferred the highest risk of progression to HCC. Patients with diabetes and coexisting hypertension and obesity may be important targets for secondary prevention.
引用
- Kanwal F, Kramer JR, Li L, et al. Effect of Metabolic Traits on the Risk of Cirrhosis and Hepatocellular Cancer in Nonalcoholic Fatty Liver Disease. Hepatology. 2020. PMID: 31675427. doi:10.1002/hep.31014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。